News Endonovo Therapeutics, Inc.

Equities

ENDV

US29272H3003

Market Closed - OTC Markets Other stock markets 02:52:12 2024-04-19 pm EDT			5-day change	1st Jan Change
0.00262 ^USD	-7.42%		-3.70%	-70.11%

2023	Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc	Mar. 28	AQ
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions	Mar. 04	AQ
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Dec. 29	CI
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million	Dec. 04	AQ
Endonovo's SofPulse® Secures Taiwan FDA Approval	23-10-12	AQ
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	23-10-12	CI
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	23-08-22	AQ
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	23-08-22	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update	23-08-08	AQ
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.	23-06-22	AQ
Endonovo Pending Agreement to Develop Telehealth Division	23-06-07	AQ
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division	23-06-07	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Endonovo Launches SofPulse® into the Veterans Administration	23-05-02	AQ
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration	23-05-02	CI
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies	23-04-25	AQ
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment	23-04-25	CI
ENDONOVO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-04-17	AQ
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Endonovo Therapeutics, Inc.

Equities

ENDV

US29272H3003

Summary

Filters